These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33120197)

  • 1. Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle.
    Garousi J; von Witting E; Borin J; Vorobyeva A; Altai M; Vorontsova O; Konijnenberg MW; Oroujeni M; Orlova A; Tolmachev V; Hober S
    Biomaterials; 2021 Jan; 266():120381. PubMed ID: 33120197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label.
    Lindbo S; Garousi J; Mitran B; Altai M; Buijs J; Orlova A; Hober S; Tolmachev V
    J Nucl Med; 2018 Jan; 59(1):93-99. PubMed ID: 28864631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6.
    Garousi J; Lindbo S; Honarvar H; Velletta J; Mitran B; Altai M; Orlova A; Tolmachev V; Hober S
    Bioconjug Chem; 2016 Nov; 27(11):2678-2688. PubMed ID: 27740752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart.
    Garousi J; Xu T; Liu Y; Vorontsova O; Hober S; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
    Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers.
    Garousi J; Lindbo S; Nilvebrant J; Åstrand M; Buijs J; Sandström M; Honarvar H; Orlova A; Tolmachev V; Hober S
    Cancer Res; 2015 Oct; 75(20):4364-71. PubMed ID: 26297736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with
    Lindbo S; Garousi J; Mitran B; Vorobyeva A; Oroujeni M; Orlova A; Hober S; Tolmachev V
    Mol Pharm; 2018 Jul; 15(7):2674-2683. PubMed ID: 29865791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion.
    Deyev SM; Oroujeni M; Garousi J; Gräslund T; Li R; Rosly AHB; Orlova A; Konovalova E; Schulga A; Vorobyeva A; Tolmachev V
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of the optimal macrocyclic chelators for labeling with
    von Witting E; Garousi J; Lindbo S; Vorobyeva A; Altai M; Oroujeni M; Mitran B; Orlova A; Hober S; Tolmachev V
    Eur J Pharm Biopharm; 2019 Jul; 140():109-120. PubMed ID: 31082509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 11. The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.
    Tolmachev V; Wållberg H; Andersson K; Wennborg A; Lundqvist H; Orlova A
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1460-8. PubMed ID: 19430786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
    Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
    Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody
    Liu Y; Vorobyeva A; Xu T; Orlova A; Loftenius A; Bengtsson T; Jonasson P; Tolmachev V; Frejd FY
    Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34200197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m.
    Garousi J; Lindbo S; Mitran B; Buijs J; Vorobyeva A; Orlova A; Tolmachev V; Hober S
    Sci Rep; 2017 Nov; 7(1):14780. PubMed ID: 29116215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein.
    Garousi J; Ding H; von Witting E; Xu T; Vorobyeva A; Oroujeni M; Orlova A; Hober S; Gräslund T; Tolmachev V
    Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours.
    Garousi J; Lindbo S; Borin J; von Witting E; Vorobyeva A; Oroujeni M; Mitran B; Orlova A; Buijs J; Tolmachev V; Hober S
    Eur J Pharm Biopharm; 2019 Jan; 134():37-48. PubMed ID: 30408518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of a Pharmacological Approach for Reduction of Renal Uptake of Radiolabeled ADAPT Scaffold Protein.
    Vorobyeva A; Oroujeni M; Lindbo S; Hober S; Xu T; Liu Y; Rinne SS; Garousi J
    Molecules; 2020 Sep; 25(19):. PubMed ID: 32998229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct In Vivo Comparison of
    Tolmachev V; Bodenko V; Oroujeni M; Deyev S; Konovalova E; Schulga A; Lindbo S; Hober S; Bragina O; Orlova A; Vorobyeva A
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Study of
    Bragina O; von Witting E; Garousi J; Zelchan R; Sandström M; Orlova A; Medvedeva A; Doroshenko A; Vorobyeva A; Lindbo S; Borin J; Tarabanovskaya N; Sörensen J; Hober S; Chernov V; Tolmachev V
    J Nucl Med; 2021 Apr; 62(4):493-499. PubMed ID: 32817142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a novel
    Liu Y; Oroujeni M; Liao Y; Vorobyeva A; Bodenko V; Orlova A; Konijnenberg M; Carlqvist M; Wahlberg E; Loftenius A; Frejd FY; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2024 Jul; ():. PubMed ID: 39008065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.